{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=5", "query": { "condition": "Neurodegenerative Disease, Hereditary", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1146, "total_pages": 115, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T13:03:35.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06826612", "title": "A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Huntington Disease" ], "interventions": [ { "name": "SPK-10001", "type": "GENETIC" }, { "name": "Placebo Surgery Control", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 53, "start_date": "2025-02-21", "completion_date": "2035-01-12", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06826612" }, { "nct_id": "NCT01568658", "title": "Genetic and Physical Study of Childhood Nerve and Muscle Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Muscular Dystrophies", "Muscle Myopathies", "Hereditary Spastic Paraplegias", "Inherited Neuropathies", "Inherited Neuromuscular Conditions" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "100 Years", "sex": "ALL", "summary": "1 Day to 100 Years" }, "enrollment_count": 2586, "start_date": "2012-03-20", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568658" }, { "nct_id": "NCT03962543", "title": "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plexiform Neurofibroma", "Neurofibromatosis Type 1 (NF1)" ], "interventions": [ { "name": "Mirdametinib (PD-0325901) oral capsule or dispersible tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 114, "start_date": "2019-09-29", "completion_date": "2028-12-22", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03962543" }, { "nct_id": "NCT00726583", "title": "Phase I Trial of Oral PX-866", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "PX-866", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cascadian Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2008-06", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 2, "location_summary": "Aurora, Colorado • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726583" }, { "nct_id": "NCT02445794", "title": "A First in Human Study of RT001 in Patients With Friedreich's Ataxia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Friedreich's Ataxia" ], "interventions": [ { "name": "Low dose cohort", "type": "DRUG" }, { "name": "High dose cohort", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biojiva LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 19, "start_date": "2015-08", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 2, "location_summary": "Long Beach, California • Tampa, Florida", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02445794" }, { "nct_id": "NCT02961283", "title": "Study of ASN003 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Melanoma", "Colorectal Neoplasm", "Carcinoma, Non-small Cell Lung" ], "interventions": [ { "name": "ASN003 ascending doses", "type": "DRUG" }, { "name": "ASN003 MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-10", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 5, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961283" }, { "nct_id": "NCT05696769", "title": "Tourette Discrimination (TD) Stigma Scale", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tourette Syndrome", "Tourette Syndrome in Children", "Tourette Syndrome in Adolescence", "Tic Disorder, Childhood", "Tics" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 43, "start_date": "2023-03-04", "completion_date": "2024-06-27", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05696769" }, { "nct_id": "NCT05797857", "title": "Exercise Training in Transthyretin Cardiac Amyloidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Amyloid Cardiomyopathy", "Transthyretin Cardiac Amyloidosis" ], "interventions": [ { "name": "Exercise Training", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 40, "start_date": "2024-07-10", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05797857" }, { "nct_id": "NCT05902351", "title": "Natural History Study for Charcot Marie Tooth Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Charcot-Marie-Tooth Disease", "Charcot-Marie-Tooth", "Charcot-Marie-Tooth Disease, Type IA", "Charcot-Marie-Tooth Disease Type 2A", "Charcot-Marie-Tooth Disease Type 2", "Charcot-Marie-Tooth Disease, Type 2C", "Charcot-Marie-Tooth Disease Type 2A2B", "Charcot-Marie-Tooth Disease Type 2B2", "Charcot-Marie-Tooth Disease Type 2A1", "Charcot-Marie-Tooth Disease Type 4B1", "Charcot-Marie-Tooth Disease, Type IB", "Charcot-Marie-Tooth Disease Type 2B1", "Charcot-Marie-Tooth Disease Type 2U (Diagnosis)", "Charcot-Marie-Tooth Disease Type 4A", "Charcot-Marie-Tooth Disease, Type 4A, Axonal Form", "Charcot-Marie-Tooth Disease Type 2A2A", "Charcot-Marie-Tooth Disease Type 2S (Disorder)", "Charcot-Marie-Tooth Disease and Deafness", "Charcot-Marie-Tooth Disease Type 4B2", "Charcot-Marie-Tooth Disease Type 4H", "Charcot-Marie-Tooth Disease Type 1F", "Charcot-Marie-Tooth Disease Type 4C", "Charcot-Marie-Tooth Disease Type 4E", "Charcot-Marie-Tooth Disease Type 1D", "Charcot-Marie-Tooth Disease Type 2Q (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2A2", "Charcot-Marie-Tooth Disease Type 2N (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2B5", "Charcot-Marie-Tooth Disease Type 2D", "Charcot-Marie-Tooth Disease Type 4D", "Charcot-Marie-Tooth Disease Type 2K", "Charcot-Marie-Tooth Disease Type 2L (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2T", "Charcot-Marie-Tooth Disease Type 2I", "Charcot-Marie-Tooth Disease Type 2J", "Charcot-Marie-Tooth Disease Type 2E", "Charcot-Marie-Tooth Disease Type 2G", "Charcot-Marie-Tooth Disease Type 1C", "Charcot-Marie-Tooth Disease Type 2R", "Charcot-Marie-Tooth Disease Type 2O (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2M", "Charcot-Marie-Tooth Disease Type 2P", "Charcot-Marie-Tooth Disease Type 2Y", "Charcot-Marie-Tooth Disease Type 4F (Diagnosis)", "Charcot-Marie-Tooth Disease Type 4B3", "Charcot-Marie-Tooth Disease Type 2H", "HNPP", "X-Linked Charcot-Marie-Tooth Disease", "Charcot Marie Tooth Disease (CMT)" ], "interventions": [], "intervention_types": [], "sponsor": "Hereditary Neuropathy Foundation", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10000, "start_date": "2013-11-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902351" }, { "nct_id": "NCT05107128", "title": "A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington's Disease" ], "interventions": [ { "name": "SAGE-718", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 189, "start_date": "2022-01-26", "completion_date": "2024-10-03", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-10-13T13:03:35.145Z", "location_count": 34, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107128" } ] }